Clinical Trials

Last Updated: 2/9/2012

Leukemia Clinical Trials are Grouped by Disease Type:

• Phase I Agents
• Acute Lymphoblastic Leukemia 
• Acute Myelogenous Leukemia
• Myelodysplastic Syndromes 
• Chronic Lymphocytic Leukemia
• Chronic Myelogenous Leukemia
• Myeloproliferative Diseases

Phase I Agents

• L-Grb2 Antisense Oligonucleotide (ALL, AML, MDS, CML) (2003-0578)
• Oral Azacitidine (AML, MDS) (2007-0405)
• RO5045337 (ALL, AML, CML) (2007-0408)
• A-dmDT390-bisFv (UCHT1) Fusion Protein (ALL, CLL) (2008-0077)
• DT388IL3 (AML, MDS) (2008-0313)
• G-CSF & Plerixafor + Sorafenib (AML) (2008-0501)
• DCC-2036 (ALL, CML) (2008-0732)
• ABT-263 (CLL) (2009-0077)
• Hyper-CVAD + RAD001 (everolimus) (ALL) (2009-0100)
• Mek Inhibitor AS703026 (ALL, AML, MDS, MPD) (2009-0195)
• Vidaza + Revlimid (AML, MDS) (2009-0467)
• Plerixafor + Clofarabine (AML) (2009-0536)
• Panobinostat + Vidaza (AML, MDS) (2009-0619)
• Nelarabine (ALL, CLL) (2009-0717)
• ABT-348 (AML, ALL, CLL, CML, MDS) (2009-0788)
• 4'-Thio-araC (ALL, AML, MDS, CLL, CML) (2009-1000)
• PF-04449913 (Hedgehog) (AML, MDS, CML, MPD) (2010-0078)
• LY2784544 (MDP) (2010-0167)
• TG02 (ALL, AML, MDS, CML, MPD) (2010-0244)
• TH-302 (ALL, AML, MDS, CLL, CML, MPD) (2010-0268)
• ON 01910.Na (ALL, AML) (2010-0303)
• PCK412 and AZA (AML, MDS) (2010-0374)
• INCB018424 (ALL, AML) (2010-0450)
• Sorafenib + 5 Aza (AML, MDS) (2010-0511)
• Oral Panobinostat + Ida + Ara-C (AML, MDS) (2010-0591)
• SGI-110 (AML, MDS) (2010-0615)
• Dasarinib + BMS-833923 (ALL, CLL) (2010-0785)
• TXA127 (MDS) (2010-0805)
• MDX-1338/BMS936564 (AML) (2010-0825)
• CA-18C3 (AML, ALL, CLL, MDS, CML) (2010-0933)
• INC424 (MPD) (2010-0964)
• PM01183 (AML, ALL, MDS, CML) (2010-0965)
• Plerixafor + G-CSF (AML) (2011-0036)
• AC220 (ASP2689) (AML, CML) (2011-0041)
• CWP232291 (AML) (2011-0253)
• AMG 900 (AML, ALL, MDS, CML) (2011-0369)
• BMS-906024 -Notch inhibitor (ALL) (2011-0382)
• LDE225 (CML) (2011-0394)
• AZD1208 (AML, MDS, MPN, CML) (2011-0816)
• ARRY-614 (MDS) (2011-0827)

Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated 

• Modified Hyper-CVAD +/- Rituximab  (ID02-230)
• Hyper-CVAD + Ofatumumab (2010-0708)
• Hyper-CVAD + Inotuzumab Ozogamycin (CMC-544) (2010-0991)
• Hyper-CVAD + Nelarabine (2006-0328)
• Hyper-CVAD + Dasatinib (SWOG0805)
• Hyper-CVAD + Ponatinib +/- Rituximab (2011-0030)
• Hyper-CVAD + Dasatinib (2006-0478)
• Hyper-CVAD + Rituximab (ID02-229)

Salvage Programs

• Blinatumomab (BiTE) (2011-0784)
• SAR 3419 (2011-0287)
• DT2219ARL (2008-0519)
• Hyper-CVAD + Ponatinib +/- Rituximab (2011-0030)
• Hyper-CVAD + Dasatinib (2006-0478)
• Nelarabine (2009-0717)
• PF-03084014 (2010-0317)
• Hyper-CVAD + RAD001 (everolimus) (2009-0100)
• 4'-Thio-araC (2009-1000)
• MOAD (2008-0267)
• INCB018424 (ALL, AML) (2010-0450)

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

• Fludarabine, Ara-C, G-CSF and Gemtuzumab Ozogamicin (2007-0147) 
• ATRA and arsenic +/- Gemtuzumab Ozogamicin (2010-0981)
• ATRA and arsenic +/- arsenic +/- idarubicin (2006-0706)
• AC220 (ASP2689) (2011-0041)
• CIA vs FLAI (2010-0788)
• Oral Panobinostat + Ida + Ara-C (2010-0591)
• Ida + Ara-C (2006-0813)
• Omacetazine + LD Ara-C (2010-0736)
• Plerixafor + Clofarabine (2009-0536)
• Cladribine + LD Ara-C alternating DAC (2011-0987)
• Sorafenib + 5 Azacitidine (2010-0511)
• Vidaza + Revlimid  (2009-0467)
• Vidaza vs Conventional Care (2009-1001)
• Sapacitabine alternating DAC (2010-0727)
• Oral Sapacitabine (2007-0727)

Newly Diagnosed FLT3 Mutated

• AC220 (ASP2689) (2011-0041)
• Ida + Ara-C + SAHA (2007-0835)
• Sorafenib + 5 Azacitidine (2010-0511)
• G-CSF & Plerixafor + Sorafenib (2008-0501)

Unfit for induction chemotheraph

• Vorinostat + Aza (2007-0685)

Salvage

• Oral Tamibarotene (APL) (2007-0512)
• Ida + Ara-C + SAHA (2007-0835)
• G-CSF & Plerixafor + Sorafenib (2008-0501)
• PCK412 and AZA (2010-0374)
• Sorafenib + 5 Azacitidine (2010-0511)
• DCC-2036 (2008-0732)
• GSK1120212 (2009-0239)
• Mek Inhibitor AS703026 (2009-0195)
• Vosaroxin + Ara-C vs Placebo + Ara-C (2010-0692)
• CIA vs FLAI (2010-0788)
• MDX-1338/BMS936564 (2010-0825)
• Plerixafor + G-CSF (2011-0036)
• MK-2206 (2010-0243)

Myelodysplastic Syndrome (MDS) (Includes CMML)

• Oral Azacitidine (2007-0405)
• Siltuximab + bsc vs placebo + bsc (2011-0548)
• Alemtuzumab (2010-0187)
• Lenalidomide VS Placebo (2009-0737)
• PCK412 and AZA (2010-0374)
• Deferasirox (2010-0041)

IPSS int-2 or high

• Vidaza + Revlimid (2009-0467)
• Oral Clofarabine (2005-0536)
• CA-18C3 (2010-0933)
• Randomized DAC alternating Clo vs DAC (2008-0092)
• Sapacitabine alternating DAC (2010-0727)
• PCK412 and AZA (2010-0374)
• Plerixafor + Clofarabine (2009-0536)
• CIA vs FLAI (2010-0788)
• PM01183 (2010-0965)
• Omacetazine + LD Ara-C (2010-0736)
• Oral Panobinostat + Ida + Ara-C (2010-0591)

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Untreated - early stage

• Ofatumumab (2010-0241)

Untreated - all stages 

• GA101 (RO5072759) + Chemo (2010-0894)
• FCR (2008-0431)
• CAL-101 + Rituximab (2010-0388)- Extension Study (2011-0612)

Mimimal Residual Disease

• Revlimid (2007-0213)
• Ofatumumab (2010-0266)

Prior Therapy

• AVL-292 (2011-0513)
• ABT-263 (2009-0077)
• Lenalidomide + Rituximab (2011-0509)
• Ofatumumab (2011-0520)
• Fludarabine + bendamustine + rituximab (2009-0546)
• Bafetinib (INNO-406) (2010-0175)
• Nelarabine (2009-0717)
• PCI-32765 (2011-0142)
• Sapacitabine + Cyclophosphamide + Rituximab (2010-0516)

Chronic Myelogenous Leukemia (CML)

Chronic phase

• BMS-354825 (2005-0422)
• Oral AMN107 (2005-0048)
• Ponatinib (AP24534) (2010-0570)
• DCC-2036 (2008-0732)
• Dasatinib + BMS-833923 (2010-0785)
• Nilotinib (2009-0683)

Accelerated Phase

• DCC-2036 (2008-0732)
• Dasatinib + BMS-833923 (2010-0785)

Blastic Phase

• DCC-2036 (2008-0732)
• DT388IL3 (2008-0313)
• Dasatinib + BMS-833923 (2010-0785)

Imatinib failures with T315l mutations (any stage)

• DCC-2036 (2008-0732)
• DT388IL3 (2008-0313)
• Dasatinib + BMS-833923 (2010-0785)

Minimal Residual Disease

• PEG-IFNa-2a (2011-0184)

Myeloproliferative Diseases

• Ruxolitinib + Revlimid (CIMF) (2011-0269)
• CYT387 (CIMF) (2011-0458)
• IPI-926 (CIMF) (2011-0445)
• INCB018424 (CIMF) (2011-0213)
• AB0024 (CIMF) (2011-0016)
• ruxolitinib (CIMF) (2011-0359)
• INC424 (CIMF) (2010-0964)
• NS-018 (CIMF) (2011-0090)
• Pomalidomide (CC-4047) (CIMF) (2007-0199)
• LY2784544 (CIMF) (2010-0167)
• Mek Inhibitor AS703026 (CIMF) (2009-0195)
• PF-04449913 (CIMF)(2010-0078)
• TH-302 (CIMF)(2010-0268)
• BMS-911543 (2010-0782)
• INC424 (PV) (2010-0808)
• Masitinib vs Placebo (SM) (2008-0275)

Supportive Care

• Ondansetron vs Ondansetron + aprepitant (2008-0615)
• Registry Study of Rasburicase (2009-0134)
• Deferasirox (2010-0041)
• Porphylactic vs Therapeutic White Cell Transfusions (2010-0468)
• Eltrombopag (2011-0319)